Gil Rabinovici, MD's Publications

Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.

Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers.

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Dissociable spatial topography of cortical atrophy in early-onset and late-onset Alzheimer's disease: A head-to-head comparison of the LEADS and ADNI cohorts.

Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-ß and tau in patients with Alzheimer's disease.

Does white matter and vascular injury from repetitive head impacts lead to a novel pattern on T2 FLAIR MRI? A hypothesis proposal and call for research.

Donanemab: Appropriate use recommendations.

Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable.

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.

Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer's disease: a neuropsychological data-driven approach.

Imaging Synaptic Density in Aging and Alzheimer Disease with [18F]SynVesT-1.

Interrogating the plasma proteome of repetitive head impact exposure and chronic traumatic encephalopathy.

Machine learning prediction of tau-PET in Alzheimer's disease using plasma, MRI, and clinical data.

Moderating effects of plasma glial fibrillary acidic protein along the Alzheimer's disease continuum.

Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotype.

Neurophysiological signatures of ageing: compensatory and compromised neural mechanisms.

Sex differences in amyloid PET in a large, real-world sample from the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study.

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment.

Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.

The Bad Medicine of Doctored.

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.

A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.

A machine learning-based prediction of tau load and distribution in Alzheimer's disease using plasma, MRI and clinical variables.

Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.

Biomarker-based staging of Alzheimer disease: rationale and clinical applications.

Blood-Based Biomarkers for Alzheimer Disease-Ready for Primary Care?

Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasia.

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.

Comorbid neuropathology and atypical presentation of Alzheimer's disease.

Comprehensive mapping of synaptic vesicle protein 2A (SV2A) in health and neurodegenerative diseases: a comparative analysis with synaptophysin and ground truth for PET-imaging interpretation.

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.

Differences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.

Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease.

Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model.

Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.

Linking Type and Extent of Head Trauma to Cavum Septum Pellucidum in Older Adults With and Without Alzheimer Disease and Related Dementias.

Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS.

Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease.

Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease.

Neurophysiological trajectories in Alzheimer's disease progression.

Neuropsychiatric Profiles and Cerebral Amyloid Burden in Adults without Dementia.

Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias.

Spatiotemporal characteristics of neurophysiological changes in patients with four-repeat tauopathies.

Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment.

The ADNI PET Core at 20.

A Step Forward in the Fight Against Dementia-Are We There Yet?

Alzheimer's disease phenotypes show different sleep architecture.

Alzheimer's pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome.

Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS).

Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.

Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort.

Brain Health Registry Study Partner Portal: Novel infrastructure for digital, dyadic data collection.

Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab.

Consensus recommendations for clinical assessment tools for the diagnosis of posterior cortical atrophy syndrome from the Atypical AD PIA of ISTAART.

Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.

Developments in understanding early onset Alzheimer's disease.

Diagnosis and Management of Posterior Cortical Atrophy.

Early-onset Alzheimer's disease explained by polygenic risk of late-onset disease?

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.

Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project.

From Clinical Trials to Memory Clinics, Tau-PET Visual Reads Can Help Diagnosis and Patient Stratification.

Functional network collapse in neurodegenerative disease.

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.

Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease.

Learning slopes in early-onset Alzheimer's disease.

Lecanemab: Appropriate Use Recommendations.

Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer's disease.

Medial Temporal Lobe Tau Aggregation Relates to Divergent Cognitive and Emotional Empathy Abilities in Alzheimer's Disease.

Network anatomy in logopenic variant of primary progressive aphasia.

Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.

Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.

Posterior cortical atrophy: clinical, neuroimaging, and neuropathological features.

Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia.

Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection.

Psychological stress is associated with arterial inflammation in people living with treated HIV infection.

Real-World Application of Anti-β-Amyloid Monoclonal Antibodies: Untangling Eligibility.

Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.

Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.

Sex-specific effects of SNAP-25 genotype on verbal memory and Alzheimer's disease biomarkers in clinically normal older adults.

Silencing tau to treat early Alzheimer's disease.

The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort.

White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).

[18F]PI-2620 Binding Patterns in Patients with Suspected Alzheimer Disease and Frontotemporal Lobar Degeneration.

Aducanumab: Appropriate Use Recommendations Update.

Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease.

Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.

ANA Investigates: The Future of Biomarkers in Alzheimer Disease.

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.

Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players.

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI.

Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.

Detection of emerging neurodegeneration using Bayesian linear mixed-effect modeling.

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.

Increasing empathic concern relates to salience network hyperconnectivity in cognitively healthy older adults with elevated amyloid-β burden.

Multi-feature computational framework for combined signatures of dementia in underrepresented settings.

Multi-Modal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinicopathological Case Series.

Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer's disease.

Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.

Rare APOE Missense Variants-Can We Overcome APOE ε4 and Alzheimer Disease Risk?

Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading.

Research Criteria for the Behavioral Variant of Alzheimer Disease: A Systematic Review and Meta-analysis.

Right temporal degeneration and socioemotional semantics: semantic behavioural variant frontotemporal dementia.

Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases.

Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials.

Tau PET Visual Reads: Research and Clinical Applications and Future Directions.

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.

The behavioral variant of Alzheimer's disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex.

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.

A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California.

Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.

Association of remote mild traumatic brain injury with cortical amyloid burden in clinically normal older adults.

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.

Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease.

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Connected speech markers of amyloid burden in primary progressive aphasia.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

Correction to: The Strategic Biomarker Roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update.

Crossed cerebellar diaschisis on 18F-FDG PET: Frequency across neurodegenerative syndromes and association with 11C-PIB and 18F-Flortaucipir.

Current directions in tau research: Highlights from Tau 2020.

Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET.

Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration.

Dominantly inherited Alzheimer's disease: a compass for drug development.

Evaluation of [18F]-JNJ-64326067-AAA tau PET tracer in humans.

Four distinct trajectories of tau deposition identified in Alzheimer's disease.

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease.

Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review.

Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry.

Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females.

New insights into atypical Alzheimer's disease in the era of biomarkers.

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.

Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease.

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Professional Soccer and Dementia Risk-The Ugly Side of the Beautiful Game.

Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease.

Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease.

Retinal imaging demonstrates reduced capillary density in clinically unimpaired APOE ε4 gene carriers.

rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data.

Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve.

Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum.

The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology.

The Rapid Naming Test: Development and initial validation in typically aging adults.

The severity of neuropsychiatric symptoms is higher in early-onset than late-onset Alzheimer's disease.

The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update.

18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.

A molecular gradient along the longitudinal axis of the human hippocampus informs large-scale behavioral systems.

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease.

Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.

Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia.

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease.

BHA-CS: A novel cognitive composite for Alzheimer's disease and related disorders.

Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia.

Diagnostic Accuracy of Amyloid versus 18 F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia.

Diagnostic Assessment in Primary Progressive Aphasia: An Illustrative Case Example.

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.

Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting.

Early Detection of Mild Cognitive Impairment (MCI) in Primary Care.

Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants.

Evaluation of a visual interpretation method for tau-PET with 18F-flortaucipir.

Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease.

Latent atrophy factors related to phenotypical variants of posterior cortical atrophy.

Longitudinal structural and metabolic changes in frontotemporal dementia.

Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity.

Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline.

Non-coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases.

Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease.

Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage.

Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease.

Predicting amyloid status using self-report information from an online research and recruitment registry: The Brain Health Registry.

Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.

Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies.

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.

Relationship Between Tau and Cognition in the Evolution of Alzheimer's Disease: New Insights from Tau PET.

Sex-related differences in the relationship between β-amyloid and cognitive trajectories in older adults.

Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.

Tau Positron Emission Tomographic Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic Encephalopathy.

The impact of demographic, clinical, genetic, and imaging variables on tau PET status.

Validation of online functional measures in cognitively impaired older adults.

18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes.

Alzheimer's disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation.

Alzheimer's pathology targets distinct memory networks in the ageing brain.

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.

Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB.

Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia.

Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease.

Cortical developmental abnormalities in logopenic variant primary progressive aphasia with dyslexia.

Dietary Supplements for Brain Health-Reply.

Late-onset Alzheimer Disease.

Legal and Policy Challenges to Addressing Cognitive Impairment in Federal Officials.

Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy.

Longitudinal tau accumulation and atrophy in aging and alzheimer disease.

Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.

Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain.

Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy.

The Rise of Pseudomedicine for Dementia and Brain Health.

A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date.

Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA.

Amyloid involvement in subcortical regions predicts cognitive decline.

Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.

Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease.

Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration.

Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.

Intrinsic connectivity networks in posterior cortical atrophy: A role for the pulvinar?

Multiproteinopathy, neurodegeneration and old age: a case study.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Prevalence of Mathematical and Visuospatial Learning Disabilities in Patients With Posterior Cortical Atrophy.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.

Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia.

Utility of Amyloid and FDG-PET in Clinical Practice: Differences Between Secondary and Tertiary Care Memory Units.

18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study.

Advances and Gaps in Understanding Chronic Traumatic Encephalopathy: From Pugilists to American Football Players.

Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Clinicopathological correlations in behavioural variant frontotemporal dementia.

Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.

Consensus classification of posterior cortical atrophy.

CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.

Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings.

Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.

Focal cerebral β-amyloid angiopathy: A distinct clinicopathologic presentation.

Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations.

Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia.

Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease.

Metabolic brain networks in aging and preclinical Alzheimer's disease.

Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia.

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Typical and atypical pathology in primary progressive aphasia variants.

Visuospatial Functioning in the Primary Progressive Aphasias.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Amyloid biomarkers: pushing the limits of early detection.

Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.

Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease.

Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins.

Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.

Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage.

Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care.

Diagnostic utility of ASL-MRI and FDG-PET in the behavioral variant of FTD and AD.

Distinct Subtypes of Behavioral Variant Frontotemporal Dementia Based on Patterns of Network Degeneration.

Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.

Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy.

Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases.

Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease.

Healthy brain connectivity predicts atrophy progression in non-fluent variant of primary progressive aphasia.

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes.

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.

Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease.

PET Imaging of Tau Deposition in the Aging Human Brain.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Progression of brain atrophy in PSP and CBS over 6 months and 1 year.

Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study.

Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort.

Sleep changes without medial temporal lobe or brain cortical changes in community-dwelling individuals with subjective cognitive decline.

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.

Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia.

A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques.

Amyloid in dementia associated with familial FTLD: not an innocent bystander.

Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease.

Blood protein predictors of brain amyloid for enrichment in clinical trials?

Cavum Septum Pellucidum in Retired American Pro-Football Players.

Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.

Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?

Evaluating and treating neurobehavioral symptoms in professional American football players: Lessons from a case series.

Executive dysfunction.

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants.

Mapping the Progression of Atrophy in Early- and Late-Onset Alzheimer's Disease.

Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.

The translational journey of brain β-amyloid imaging: from positron emission tomography to autopsy to clinic.

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Amyloid imaging in atypical dementia.

Anomalous functional language lateralization in semantic variant PPA.

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.

Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy.

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.

Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.

Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.

Handedness and language learning disability differentially distribute in progressive aphasia variants.

Imaging markers for Alzheimer disease: which vs how.

Imaging prodromal FTD: seeing the future through PET crystals.

Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease.

Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease.

Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology.

Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia.

Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load.

Practical utility of amyloid and FDG-PET in an academic dementia center.

Prodromal posterior cortical atrophy: clinical, neuropsychological, and radiological correlation.

Progranulin mutations as risk factors for Alzheimer disease.

Seizures and epileptiform activity in the early stages of Alzheimer disease.

A 44-year-old man with profound behavioural changes.

ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease.

Association of lifetime cognitive engagement and low β-amyloid deposition.

Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion.

Posterior cortical atrophy.

Shining a light on posterior cortical atrophy.

Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

White matter atrophy in Alzheimer's disease variants.

Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications.

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease.

Clinicopathological correlations in corticobasal degeneration.

Corticobasal syndrome: overcoming the artificial divide between disorders of cognition and movement.

Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution.

Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.

Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant.

Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging.

Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease.

Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.

Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease.

Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB).

Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI.

Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Patient management problem.

Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum.

Seizures in corticobasal degeneration: a case report.

Sporadic corticobasal syndrome due to FTLD-TDP.

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Frontotemporal lobar degeneration: clinical and pathologic overview.

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.

Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease.

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.

Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration.

Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration.

First symptom in sporadic Creutzfeldt-Jakob disease.

Hypoglycemic and hypoxic modulation of cortical micro-EEG activity in rat brain slices.